Table 3. Predicted anti-HPV-16 and -18 antibody responses by piece-wise and modified power-law models.
| Antigen | Natural infection levels† (EL.U/mL) | Piece-wise model | Modified power-law model | ||
|---|---|---|---|---|---|
| Predicted GMT (EL.U/mL) | Predicted time* (years) | Predicted GMT (EL.U/mL) | Predicted time* (years) | ||
| Statistical model - based on data up to 7·3 y | |||||
| HPV-16 | 29·8 | 177·9 | 24·7 | 319·7 | Always |
| HPV-18 | 22·6 | 88·8 | 18·2 | 219·3 | Always |
| Statistical model - based on data up to 8·4 y | |||||
| HPV-16 | 29·8 | 213·0 | 29·3 | 312·8 | Always |
| HPV-18 | 22·6 | 92·4 | 18·9 | 207·7 | Always |
| Statistical model - based on data up to 9·4 y | |||||
| HPV-16 | 29·8 | 235·2 | 32·3 | 305·2 | Always |
| HPV-18 | 22·6 | 106·2 | 20·5 | 247·1 | Always |
*
Predicted time ensuring that 95% of women will still have levels above natural infection levels. EL.U/mL = ELISA units/mL;†Natural infection IgG; GMTs correspond to the geometric mean titer of ‘cleared’ natural infection (i.e., subjects DNA-negative and seropositive at the time of enrolment), obtained from the Phase III study (HPV-008, NCT00122681), as benchmarks.16